Efficacy and safety of stem cell therapy for erectile dysfunction: A systematic review and Meta-analysis.
- Author:
Ming-Hui HUANG
1
;
Jia-Yu ZHAO
2
;
Xue-Jun SHANG
3
;
Yong-Jun LIU
2
Author Information
1. Faculty of Continuing Education， China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
2. School of International Pharmaceutical Business， China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
3. Department of Urology， Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University / General Hospital of Eastern Theater Command，Nanjing, Jiangsu 210002， China.
- Publication Type:English Abstract
- Keywords:
erectile dysfunction;
stem cell therapy;
Meta-analysis
- MeSH:
Humans;
Erectile Dysfunction/therapy*;
Male;
Stem Cell Transplantation/adverse effects*;
Treatment Outcome;
Stem Cells
- From:
National Journal of Andrology
2025;31(6):535-546
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the safety, efficacy and potential impact of stem cell therapy (SCT) in improving erectile dysfunction (ED).
METHODS:A comprehensive search strategy was used to search the literatures on safety and efficacy evaluation of stem cell (SC) in the treatment of ED by human clinical trials from PubMed, Embase and Web of science databases with a search time frame from database creation to July 4, 2024. The exclusion criteria were as follows: reviews, conference abstracts, animal experiments, and duplicate sample literature.
RESULTS:The study initially screened 1 773 papers, and 17 were included in the final analysis. These studies involved a total of 269 ED patients, and a variety of sources of stem cells had been used in the treatment of ED, including adipose-derived stem cells, bone marrow-derived stem cells, placental stroma-derived stem cells, umbilical cord-derived stem cells, dental pulp-derived stem cells, and oral mucosa-derived stem cells. All studies were conducted by injecting stem cells into the cavernous body of the penis, but there is no fixed standard for the amount of injection, injection site and number of injections. The optimal treatment mode was still being explored. Patients' International Index of Erectile Function (IIEF) scores and Erection Hardness Score (EHS), peak systolic velocity (PSV), and end diastolic velocity (EDV) improved after treatment. But some studies showed that the efficacy of the treatment diminished with increasing time. No serious adverse effects were reported in any of the studies and none of the adverse effects persisted for a long period of time. The most common adverse effects included injection site reactions, and SCT showed a good safety and tolerability profile.
CONCLUSION:SCT has the potential to be a promising and innovative regenerative therapy option for ED patients. In the future, with the advancement of stem cell technology, larger randomized controlled studies should continue to be conducted to explore standardized treatments, so as to further evaluate the long-term efficacy and safety of SCT for ED.
